세계의 지카열 백신 시장 규모 : 백신 유형별, 용도별, 지역 범위별, 예측

Zika Vaccines Market Size And Forecast

Zika Vaccines Market size was valued at USD 13,691 Million in 2024 and is projected to reach USD 19,789 Million by 2031, growing at a CAGR of 5.4% from 2024 to 2031.

The increased prevalence of Zika virus disease in countries is driving the global Zika Vaccines Market forward. Major pharmaceutical companies that have increased the investment in R&D for the production of new vaccines is driving the global market's expansion. In addition, there has been an increase in outreach campaigns and a partnership study for vaccine development with the World Health Organization which is driving the growth of Zika Vaccines Market. The Global Zika Vaccines Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Zika Vaccines Market Definition

Zika virus (ZIKV), also known as a flavivirus, that is from the Flaviviridae family, is a mosquito-borne disease that spreads to humans through mosquitos, blood transfusions, sex, and from an infected pregnant woman to her baby. After biting a zika-infected human, a mosquito becomes infected with the virus and spreads it to anyone they sting. Infection with the Zika virus may result in neurological abnormalities and congenital birth defects in the fetus. Zika vaccines are being designed to help people prevent and manage diseases caused by the Zika virus.

There are many varieties of vaccines used to protect against the Zika virus, including mRNA vaccines, DNA vaccines, and inactivated vaccines. In addition, the virus can be transmitted from an infected pregnant woman to her fetus. PCR is used for the diagnosis of the infection. However, only 1 out of every 4 people with the virus has the risk of developing symptoms. In November 2016, the World Health Organization (WHO) announced that the Zika virus is no longer a threat to public health, which has been an international concern since the major cases of the virus are asymptomatic.

Global Zika Vaccines Market Overview

The increasing prevalence of the active Zika virus as well as increased concern about the consequences of the Zika virus has increased the market for Zika vaccines and is the primary factor driving the global Zika virus vaccine demand. The rising prevalence of Zika fever is fueling the production of effective vaccines. The growing public understanding of the virus is encouraging the use of these vaccines which in turn is driving the market. Increased investment in vaccine research and development, as well as favorable government policies, are also the growth drivers for the Zika Vaccines Market.

In addition, the increase in demand for zika virus and advancements in vaccine technologies are expected to help in business growth and development. However, the factors restraining the market growth and development are a lack of affordability and a lack of recognition and awareness in remote areas. Also, the lack of knowledge in using advanced technology in underdeveloped countries is also restraining the market growth. In addition, these vaccines might cause some harmful effects on the body of individuals which in turn can restrain the market growth.

Global Zika Vaccines Market: Segmentation Analysis

The Global Zika Vaccines Market is segmented based on Vaccine Type, Application, and Geography.

Zika Vaccines Market, By Vaccine Type

Inactivated Vaccine

Purified Inactivated Vaccine

DNA Vaccine

Based on Vaccine Type, the market is bifurcated into Inactivated Vaccine, Purified Inactivated Vaccine, and DNA Vaccine. Inactivated Vaccine dominated the market in 2019 and is likely to continue in the forecast period. Purified Inactivated Vaccine has good market potentials in the forecast period owing to the evolution of modern medicines and equipment technologies.

Zika Vaccines Market, By Application

Clinics

Academic and Research

Hospitals

Others

Based on Application, the market is bifurcated into Clinics, Academic and Research, Hospitals, and Others. The hospital segment accounted for the strongest share in 2019, and this pattern is expected to continue. An increase in patients with Zika virus disease would necessitate hospitalization. Also, the early availability of new drugs in hospitals is expected to fuel the segment's development.

Zika Vaccines Market, By Geography

North America

Europe

Asia Pacific

Rest of the world

Based on regional analysis, the Global Zika Vaccines Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. In 2019, the Rest of the world led the global Zika Vaccines Market, and this pattern is projected to continue over the years. The region's domination can be due to a rise in people infected with the Zika virus in countries such as Brazil, Bolivia, and Peru, as well as the involvement of major players.

Key Players

The "Global Zika Vaccines Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Inovio Pharmaceuticals, Inc., Emergent BioSolutions Inc., Gilead Sciences Inc., Precigen, Inc., LUMOS PHARMA, Hawaii Biotech Inc., Sanofi, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, and Bharat Biotech.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

• Ace Matrix Analysis
• The Ace Matrix provided in the report would help to understand how the major key players involved in this industry are performing as we provide a ranking for these companies based on various factors such as service features & innovations, scalability, innovation of services, industry coverage, industry reach, and growth roadmap. Based on these factors, we rank the companies into four categories as Active, Cutting Edge, Emerging, and Innovators.
• Market Attractiveness
• The image of market attractiveness provided would further help to get information about the region that is majorly leading in the global Zika Vaccines market. We cover the major impacting factors that are responsible for driving the industry growth in the given region.
• Porter's Five Forces
• The image provided would further help to get information about Porter's five forces framework providing a blueprint for understanding the behavior of competitors and a player's strategic positioning in the respective industry. The porter's five forces model can be used to assess the competitive landscape in global Zika Vaccines market, gauge the attractiveness of a certain sector, and assess investment possibilities.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL ZIKA VACCINES MARKET

• 1.1 Market Definition
• 1.2 Market Segmentation
• 1.3 Research Timelines
• 1.4 Assumptions
• 1.5 Limitations

2 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 2.1 Data Mining
• 2.2 Data Triangulation
• 2.3 Bottom-Up Approach
• 2.4 Top-Down Approach
• 2.5 Research Flow
• 2.6 Key Insights from Industry Experts
• 2.7 Data Sources

3 EXECUTIVE SUMMARY

• 3.1 Market Overview
• 3.2 Ecology Mapping
• 3.3 Absolute Market Opportunity
• 3.4 Market Attractiveness
• 3.5 Global Zika Vaccines Market Geographical Analysis (CAGR %)
• 3.6 Global Zika Vaccines Market, By Vaccine Type (USD Million)
• 3.7 Global Zika Vaccines Market, By Application (USD Million)
• 3.8 Future Market Opportunities
• 3.9 Global Market Split
• 3.10 Product Life Line

4 GLOBAL ZIKA VACCINES MARKET OUTLOOK

• 4.1 Global Zika Vaccines Evolution
• 4.2 Drivers
  • 4.2.1 Driver 1
  • 4.2.2 Driver 2
• 4.3 Restraints
  • 4.3.1 Restraint 1
  • 4.3.2 Restraint 2
• 4.4 Opportunities
  • 4.4.1 Opportunity 1
  • 4.4.2 Opportunity 2
• 4.5 Porters Five Force Model
• 4.6 Value Chain Analysis
• 4.7 Pricing Analysis
• 4.8 Macroeconomic Analysis

5 GLOBAL ZIKA VACCINES MARKET, BY VACCINE TYPE

• 5.1 Overview
• 5.2 Inactivated Vaccine
• 5.3 Purified Inactivated Vaccine
• 5.4 DNA Vaccine

6 GLOBAL ZIKA VACCINES MARKET, BY APPLICATION

• 6.1 Overview
• 6.2 Clinics
• 6.3 Academic and Research
• 6.4 Hospitals
• 6.5 Others

7 GLOBAL ZIKA VACCINES MARKET, BY GEOGRAPHY

• 7.1 Overview
• 7.2 North America
  • 7.2.1 U.S.
  • 7.2.2 Canada
  • 7.2.3 Mexico
• 7.3 Europe
  • 7.3.1 Germany
  • 7.3.2 U.K.
  • 7.3.3 France
  • 7.3.4 Italy
  • 7.3.5 Spain
  • 7.3.6 Rest of Europe
• 7.4 Asia Pacific
  • 7.4.1 China
  • 7.4.2 Japan
  • 7.4.3 India
  • 7.4.4 Rest of Asia Pacific
• 7.5 Latin America
  • 7.5.1 Brazil
  • 7.5.2 Argentina
  • 7.5.3 Rest of Latin America
• 7.6 Middle-East and Africa
  • 7.6.1 UAE
  • 7.6.2 Saudi Arabia
  • 7.6.3 South Africa
  • 7.6.4 Rest of Middle-East and Africa

8 GLOBAL ZIKA VACCINES MARKET COMPETITIVE LANDSCAPE

• 8.1 Overview
• 8.2 Company Market Ranking
• 8.3 Key Developments
• 8.4 Company Regional Footprint
• 8.5 Company Industry Footprint
• 8.6 ACE Matrix

9 COMPANY PROFILES

• 9.1 Inovio Pharmaceuticals Inc
  • 9.1.1 Company Overview
  • 9.1.2 Company Insights
  • 9.1.3 Product Benchmarking
  • 9.1.4 Key Development
  • 9.1.5 Winning Imperatives
  • 9.1.6 Current Focus & Strategies
  • 9.1.7 Threat from Competition
  • 9.1.8 SWOT Analysis
• 9.2 Emergent BioSolutions Inc
  • 9.2.1 Overview
  • 9.2.2 Financial Performance
  • 9.2.3 Product Outlook
  • 9.2.4 Key Developments
• 9.3 Gilead Sciences Inc
  • 9.3.1 Overview
  • 9.3.2 Financial Performance
  • 9.3.3 Product Outlook
  • 9.3.4 Key Developments
• 9.4 Precigen Inc
  • 9.4.1 Overview
  • 9.4.2 Financial Performance
  • 9.4.3 Product Outlook
  • 9.4.4 Key Developments
• 9.5 LUMOS PHARMA
  • 9.5.1 Overview
  • 9.5.2 Financial Performance
  • 9.5.3 Product Outlook
  • 9.5.4 Key Developments
• 9.6 Hawaii Biotech Inc
  • 9.6.1 Overview
  • 9.6.2 Financial Performance
  • 9.6.3 Product Outlook
  • 9.6.4 Key Developments
• 9.7 Sanofi
  • 9.7.1 Overview
  • 9.7.2 Financial Performance
  • 9.7.3 Product Outlook
  • 9.7.4 Key Developments
• 9.8 GlaxoSmithKline plc
  • 9.8.1 Overview
  • 9.8.2 Financial Performance
  • 9.8.3 Product Outlook
  • 9.8.4 Key Developments
• 9.9 Takeda Pharmaceutical Company Limited
  • 9.9.1 Overview
  • 9.9.2 Financial Performance
  • 9.9.3 Product Outlook
  • 9.9.4 Key Developments
• 9.10 Bharat Biotech
  • 9.10.1 Overview
  • 9.10.2 Financial Performance
  • 9.10.3 Product Outlook
  • 9.10.4 Key Developments

10 VERIFIED MARKET INTELLIGENCE

• 10.1 About Verified Market Intelligence
• 10.2 Dynamic Data Visualization